GentiBio
Marko Repic is an Associate Director of Toxicology and Preclinical Safety in the Translational Sciences Team. Marko joined GentiBio from MC Toxicology Consulting where he provided nonclinical and toxicology consulting services to many leading companies in the cell and gene therapy space. Marko has extensive experience establishing and executing innovative non-clinical development strategies and a keen interest in unraveling mechanisms behind peculiar toxicological observations. His key achievements include the successful advancement of several viral gene therapies, gene editing, regenerative medicine, and immuno-oncology programs into the first-in-human studies. Marko completed his Ph.D. and Post-Doctoral fellowship at the Institute of Molecular Biotechnology (IMBA) at the University of Vienna.
This person is not in any offices
GentiBio
GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system.